Document Type: Original Research

Authors

1 Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran

2 Oncopathology Research Center, Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Department of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background & Objective: Colorectal cancer (CRC) is the third most common cancer worldwide with a high mortality rate. The main causes of death in patients are recurrence and metastasis which are mainly attributed to the small subpopulation of cells within tumors called cancer stem cells (CSCs). This study aimed to evaluate the correlation between the expression of AHDL1 and CD133 as CSC associated markers and clinicopathological characteristics in CRC.
Methods: In this cross-sectional study, a total of 483 CRC tumor samples were immunohistochemically stained for detection of CD133 and ALDH1 markers. Correlations of marker expression with clinicopathological factors were also evaluated.
Results: There was a significant correlation between the luminal intensity of CD133 and neural invasion (p =0.05) and between the cytoplasmic intensity of CD133 and metastasis (p =0.05). In terms of H-score, a positive significant relation was observed between cytoplasmic expression of CD133 and lymph node (p =0.02), neural (p =0.04) and vascular invasion (p =0.02). The ALDH1 cytoplasmic expression showed a significant correlation with tumor size (p =0.001).
Conclusion: Our findings showed that increased expression of CD133 and ALDH1 is associated with tumor progression and worse outcomes in CRC patients. These markers can be good candidates for localized targeting of CSCs using antibodies. Future researches need to be improved approaches for early detection of CRC, and treatment monitoring for CRC and other cancers.

Keywords

Main Subjects

  1. Sadek SA, DM AR, Fatima S. The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5. Indian J Pathol Microbiol. 2020;63(1):32-7. [DOI:10.4103/IJPM.IJPM_154_19] [PMID]
  2. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014;64(2):104-17. [DOI:10.3322/caac.21220] [PMID]
  3. Stewart BW, Kleihues P. World cancer report. 2003.
  4. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. [DOI:10.3390/ijms18010197] [PMID] [PMCID]
  5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67. [DOI:10.1016/0092-8674(90)90186-I]
  6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-56. [DOI:10.1038/nrc1739] [PMID]
  7. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer medicine. 2013;2(4):496-506. [DOI:10.1002/cam4.97] [PMID] [PMCID]
  8. Herzig DO, Tsikitis VL. Molecular markers for colon diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015;111(1):96-102. [DOI:10.1002/jso.23806] [PMID]
  9. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013;8(6):e65479. [DOI:10.1371/journal.pone.0065479] [PMID] [PMCID]
  10. Sarli L, Bottarelli L, Bader G, Iusco D, Pizzi S, Costi R, et al. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rectum. 2004;47(9):1467-82. [DOI:10.1007/s10350-004-0628-6] [PMID]
  11. Vaz MA, Martinez JC, Devesa JM, Trill JD, Abraira V, Riquelme A, et al. Prognostic value of stem cell quantification in stage II colon cancer. PLoS One. 2014;9(2):e88480. [DOI:10.1371/journal.pone.0088480] [PMID] [PMCID]
  12. Huang R, Mo D, Wu J, Ai H, Lu Y. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. Medicine (Baltimore). 2018;97(23):e10446. [DOI:10.1097/MD.0000000000010446] [PMID] [PMCID]
  13. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012;13(2):e83-9. [DOI:10.1016/S1470-2045(11)70257-1]
  14. Boman B, Wicha M. Cancer Stem Cells: A Step toward the Cure. American Society of Clinical Oncology. 2008; 26 (17): 2795-2799. [DOI:10.1200/JCO.2008.17.7436] [PMID]
  15. Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol. 2009;27(1):44-6. [DOI:10.1038/nbt0109-44] [PMID]
  16. Zhou J-Y, Chen M, Ma L, Wang X, Chen Y-G, Liu S-L. Role of CD44high/CD133high HCT-116 cells in the tumorigenesis of colon cancer. Oncotarget. 2016;7(7):7657. [DOI:10.18632/oncotarget.7084] [PMID] [PMCID]
  17. Leng Z, Xia Q, Chen J, Li Y, Xu J, Zhao E, et al. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer. Cell Physiol Biochem. 2018;46(2):860-72. [DOI:10.1159/000488743] [PMID]
  18. Cherciu I, Barbalan A, Pirici D, Margaritescu C, Saftoiu A. Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr Health Sci J. 2014;40(3):153-61.
  19. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells. 2012;30(3):363-71. [DOI:10.1002/stem.1031] [PMID]
  20. Thenappan A, Li Y, Shetty K, Johnson L, Reddy EP, Mishra L. New Therapeutics Targeting Colon Cancer Stem Cells. Curr Colorectal Cancer Rep. 2009;5(4):209. [DOI:10.1007/s11888-009-0029-2] [PMID] [PMCID]
  21. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10. [DOI:10.1038/nature05372] [PMID]
  22. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90(12):5013-21. [DOI:10.1182/blood.V90.12.5013] [PMID]
  23. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2001;2(2):82-91. [DOI:10.1034/j.1600-0854.2001.020202.x] [PMID]
  24. Cheng J-X, Liu B-L, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009;35(5):403-8. [DOI:10.1016/j.ctrv.2009.03.002] [PMID]
  25. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117(Pt 16):3539-45. [DOI:10.1242/jcs.01222] [PMID]
  26. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008;68(23):9703-11. [DOI:10.1158/0008-5472.CAN-08-3084] [PMID] [PMCID]
  27. Wang K, Xu J, Zhang J, Huang J. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer. 2012;12(1):573. [DOI:10.1186/1471-2407-12-573] [PMID] [PMCID]
  28. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5. [DOI:10.1038/nature05384] [PMID]
  29. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 2008;15(2):638-48. [DOI:10.1245/s10434-007-9605-3] [PMID]
  30. Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. AMA Arch Surg. 2012;147(1):18-24. [DOI:10.1001/archsurg.2011.795] [PMID]
  31. Chen J, Xia Q, Jiang B, Chang W, Yuan W, Ma Z, et al. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(12):e0145164. [DOI:10.1371/journal.pone.0145164] [PMID] [PMCID]
  32. Vishnubalaji R, Manikandan M, Fahad M, Hamam R, Alfayez M, Kassem M, et al. Molecular profiling of ALDH1(+) colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget. 2018;9(17):13551-64. [DOI:10.18632/oncotarget.24420] [PMID] [PMCID]
  33. Kozovska Z, Patsalias A, Bajzik V, Durinikova E, Demkova L, Jargasova S, et al. ALDH1A inhibition sensitizes colon cancer cells to chemotherapy. BMC Cancer. 2018;18(1):656. [DOI:10.1186/s12885-018-4572-6] [PMID] [PMCID]
  34. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15(12):4234-41. [DOI:10.1158/1078-0432.CCR-08-1479] [PMID]
  35. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102(5):340-51. [DOI:10.1093/jnci/djp535] [PMID] [PMCID]
  36. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL. Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res. 2010;3(1):28. [DOI:10.1186/1757-2215-3-28] [PMID] [PMCID]
  37. Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, et al. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer. 2011;10(1):96. [DOI:10.1186/1476-4598-10-96] [PMID] [PMCID]
  38. Moreb J, Zucali J, Zhang Y, Colvin M, Gross M. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1β and tumor necrosis factor. Cancer Res. 1992;52(7):1770-4.
  39. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell. 2007;1(5):555-67. [DOI:10.1016/j.stem.2007.08.014] [PMID] [PMCID]
  40. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69(8):3382-9. [DOI:10.1158/0008-5472.CAN-08-4418] [PMID] [PMCID]
  41. Deng Y, Zhou J, Fang L, Cai Y, Ke J, Xie X, et al. ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. Br J Cancer. 2014;110(2):430-4. [DOI:10.1038/bjc.2013.767] [PMID] [PMCID]
  42. O'Dwyer D, Ralton LD, O'Shea A, Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One. 2011;6(11):e27718. [DOI:10.1371/journal.pone.0027718] [PMID] [PMCID]
  43. Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014;110(12):2935-44. [DOI:10.1038/bjc.2014.226] [PMID] [PMCID]
  44. Sedaghat S, Gheytanchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Appl Immunohistochem Mol Morphol. 2017;25(3):196-202. [DOI:10.1097/PAI.0000000000000291] [PMID]
  45. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80(12):1943-9. [DOI:10.1038/labinvest.3780204] [PMID]
  46. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313-9. [DOI:10.1038/nm.2304] [PMID]
  47. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67(19):8980-4. [DOI:10.1158/0008-5472.CAN-07-0895] [PMID]
  48. Chen S, Song X, Chen Z, Li X, Li M, Liu H, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2013;8(2):e56380. [DOI:10.1371/journal.pone.0056380] [PMID] [PMCID]
  49. He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother. 2014;68(5):507-13. [DOI:10.1016/j.biopha.2014.03.016] [PMID]
  50. Li C-Y, Li B-X, Liang Y, Peng R-Q, Ding Y, Xu D-Z, et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med. 2009;7(1):56. [DOI:10.1186/1479-5876-7-56] [PMID] [PMCID]
  51. Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, et al. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol. 2012;47(10):1211-7. [DOI:10.3109/00365521.2012.694904] [PMID]
  52. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009;27(8):844-50. [DOI:10.1080/07357900902744502] [PMID]
  53. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008;99(8):1578-83. [DOI:10.1111/j.1349-7006.2008.00849.x] [PMID]
  54. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 2009;55(3):284-93. [DOI:10.1111/j.1365-2559.2009.03378.x] [PMID]
  55. Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci. 2010;101(4):906-12. [DOI:10.1111/j.1349-7006.2009.01478.x] [PMID]
  56. García VM, Batlle J, Casado E, Burgos E, de Castro J, Belda C, et al. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis. 2011;13(9):989-98. [DOI:10.1111/j.1463-1318.2010.02386.x] [PMID]
  57. Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y, et al. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011;31(2):495-500.
  58. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31(1):71. [DOI:10.1186/1756-9966-31-71] [PMID] [PMCID]
  59. Li H, Zhao P, Lu Y, Lu Y. Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma. Int J Colorectal Dis. 2012;27(8):1015-20. [DOI:10.1007/s00384-012-1421-y] [PMID]
  60. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99(8):1285-9. [DOI:10.1038/sj.bjc.6604664] [PMID] [PMCID]
  61. Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. Oral Oncol. 2014;50(12):1144-8. [DOI:10.1016/j.oraloncology.2014.08.018] [PMID]
  62. Korfias D, Contis J, Frangou-Plemenou M, Gennatas K, Kondis A, Vlachodimitropoulos D. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases. Eur J Gynaecol Oncol. 2020;41(1):36-41. [DOI:10.31083/j.ejgo.2020.01.4810]
  63. Zhou F, Mu YD, Liang J, Liu ZX, Chen HS, Zhang JF. Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett. 2014;7(2):507-12. [DOI:10.3892/ol.2013.1723] [PMID] [PMCID]
  64. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103(3):382-90. [DOI:10.1038/sj.bjc.6605762] [PMID] [PMCID]
  65. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer. 2014;14(1):444. [DOI:10.1186/1471-2407-14-444] [PMID] [PMCID]
  66. Koren A, Rijavec M, Kern I, Sodja E, Korosec P, Cufer T. BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma. Stem Cells Int. 2016;2016:9714315. [DOI:10.1155/2016/9714315] [PMID] [PMCID]
  67. Liu WT, Liu WB, Gao M, Zhang YY, Gu KS. Expression of ALDH1A1 and CD133 is associated with the prognosis and effect of different chemotherapeutic regimens in gastric cancer. Oncol Lett. 2019;18(5):4573-82. [DOI:10.3892/ol.2019.10798] [PMID] [PMCID]